Active Ingredient History

  • Now
Axitinib (trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. It was approved by the U.S. Food and Drug Administration.   NCATS

  • SMILES: CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(\C=C\C4=CC=CC=N4)=NN3
  • Mol. Mass: 386.47
  • ALogP: 4.64
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)


$14.7049 - $70.5265

United States

$62.2408 - $245.5933
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ag013736 | ag 013736 | ag-013736 | ag-103736 | ag-13736 | ag 6013736 | axitinib | axitinibum | inlyta


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue